Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

Published:2023-03 Issue: Volume:57 Page:101866
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Attauabi Mohamed^ORCID,Dahl Emilie Kristine^ORCID,Burisch Johan^ORCID,Gubatan John^ORCID,Nielsen Ole Haagen^ORCID,Seidelin Jakob Benedict^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference58 articles.

1. Ulcerative colitis;Kobayashi;Nat Rev Dis Prim,2020

2. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis;Ford;Am J Gastroenterol,2011

3. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults;Lamb;Gut,2019

4. Tumor necrosis factor inhibitors for inflammatory bowel disease;Nielsen;N Engl J Med,2013

5. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study;Zhao;Aliment Pharmacol Ther,2022

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management;World Journal of Gastroenterology;2024-09-21

2. Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis;Frontiers in Immunology;2024-08-30

3. In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis;Inflammatory Bowel Diseases;2024-08-20

4. Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons;Advances in Therapy;2024-08-10

5. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3